London · Delayed Price · Currency is GBP · Price in GBX Kromek Group Earnings Call Transcripts
Fiscal Year 2026
-
FY 2027 revenue is guided at GBP 30.3 million, with a midterm target of GBP 60 million and 30% EBITDA margin by 2030/2031. Growth is driven by both Advanced Imaging and CBRN, with capacity expansion funded by customers and sufficient working capital facilities in place.
-
Revenue reached GBP 27.1 million with 36% underlying growth, driven by advanced imaging and CBRN detection. Profit before tax was GBP 2.5 million, and the business is well-positioned for continued expansion, with new commercial opportunities in biosecurity and a robust pipeline.
-
Strong growth in the CZT detector market is driving profitability, with major contracts and a shift to a licensing-heavy model. The company targets £60 million revenue and 30% EBITDA margin in the medium term, supported by robust demand in medical imaging and CBRN, while maintaining independence and disciplined capital allocation.
Fiscal Year 2025
-
Profitability and revenue growth were driven by the Siemens deal, strong contract wins, and expanding CBRN and biosecurity segments. Gross margin rose to 81%, and the company targets £60M revenue and 30% EBITDA margin by 2030, with continued year-on-year profit expected.
-
Two clear growth pillars—advanced imaging and CBRN detection—are driving a midterm target of £60 million revenue and 30–35% EBITDA within five years, supported by strong contract wins, stable margins, and disciplined M&A. Focus remains on organic growth, operational excellence, and expanding in key global markets.
-
Two core business segments—Advanced Imaging and CBRN Detection—are positioned for accelerated growth, leveraging proprietary technology, high entry barriers, and strong customer relationships. FY2025 saw record revenue and a shift to profitability, with a robust pipeline, disciplined capital allocation, and a midterm target of £60M revenue and 30% EBITDA.
-
Record revenue and EBITDA positive performance driven by strong growth in advanced imaging and CBRN segments, with improved gross margin and reduced losses. Robust contract pipeline and market positioning support a positive outlook, while cost control and cash management remain priorities.